ENO1 and neoplasm: Consistently, in the KrasG12D/Trp53R172H/Cre mouse model of PDAC, vaccination of the mice with the DNA of ENO1 elicits significant anti-tumor immune responses, thereby delaying tumor progression and extending survival (39).